<?xml version='1.0' encoding='utf-8'?>
<document id="25854986"><sentence text="Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK."><entity charOffset="49-61" id="DDI-PubMed.25854986.s1.e0" text="cabozantinib" /><entity charOffset="87-95" id="DDI-PubMed.25854986.s1.e1" text="rifampin" /><entity charOffset="110-122" id="DDI-PubMed.25854986.s1.e2" text="ketoconazole" /><entity charOffset="126-138" id="DDI-PubMed.25854986.s1.e3" text="cabozantinib" /><entity charOffset="163-175" id="DDI-PubMed.25854986.s1.e4" text="cabozantinib" /><entity charOffset="202-215" id="DDI-PubMed.25854986.s1.e5" text="rosiglitazone" /><pair ddi="false" e1="DDI-PubMed.25854986.s1.e0" e2="DDI-PubMed.25854986.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25854986.s1.e0" e2="DDI-PubMed.25854986.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25854986.s1.e0" e2="DDI-PubMed.25854986.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25854986.s1.e0" e2="DDI-PubMed.25854986.s1.e3" /><pair ddi="false" e1="DDI-PubMed.25854986.s1.e0" e2="DDI-PubMed.25854986.s1.e4" /><pair ddi="false" e1="DDI-PubMed.25854986.s1.e0" e2="DDI-PubMed.25854986.s1.e5" /><pair ddi="false" e1="DDI-PubMed.25854986.s1.e1" e2="DDI-PubMed.25854986.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25854986.s1.e1" e2="DDI-PubMed.25854986.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25854986.s1.e1" e2="DDI-PubMed.25854986.s1.e3" /><pair ddi="false" e1="DDI-PubMed.25854986.s1.e1" e2="DDI-PubMed.25854986.s1.e4" /><pair ddi="false" e1="DDI-PubMed.25854986.s1.e1" e2="DDI-PubMed.25854986.s1.e5" /><pair ddi="false" e1="DDI-PubMed.25854986.s1.e2" e2="DDI-PubMed.25854986.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25854986.s1.e2" e2="DDI-PubMed.25854986.s1.e3" /><pair ddi="false" e1="DDI-PubMed.25854986.s1.e2" e2="DDI-PubMed.25854986.s1.e4" /><pair ddi="false" e1="DDI-PubMed.25854986.s1.e2" e2="DDI-PubMed.25854986.s1.e5" /><pair ddi="false" e1="DDI-PubMed.25854986.s1.e3" e2="DDI-PubMed.25854986.s1.e3" /><pair ddi="false" e1="DDI-PubMed.25854986.s1.e3" e2="DDI-PubMed.25854986.s1.e4" /><pair ddi="false" e1="DDI-PubMed.25854986.s1.e3" e2="DDI-PubMed.25854986.s1.e5" /><pair ddi="false" e1="DDI-PubMed.25854986.s1.e4" e2="DDI-PubMed.25854986.s1.e4" /><pair ddi="false" e1="DDI-PubMed.25854986.s1.e4" e2="DDI-PubMed.25854986.s1.e5" /></sentence><sentence text="Cabozantinib is a small-molecule tyrosine kinase inhibitor that has been approved for the treatment of patients with progressive, metastatic medullary thyroid cancer"><entity charOffset="0-12" id="DDI-PubMed.25854986.s2.e0" text="Cabozantinib" /><entity charOffset="33-41" id="DDI-PubMed.25854986.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.25854986.s2.e0" e2="DDI-PubMed.25854986.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25854986.s2.e0" e2="DDI-PubMed.25854986.s2.e1" /></sentence><sentence text=" In vitro data indicate that (1) cytochrome P450 (CYP) 3A4 is the primary CYP isoenzyme involved in the metabolism of cabozantinib, and (2) CYP2C8 is the CYP isoenzyme most potently inhibited by cabozantinib with potential for in vivo inhibition at clinically relevant plasma exposures"><entity charOffset="118-130" id="DDI-PubMed.25854986.s3.e0" text="cabozantinib" /><entity charOffset="195-207" id="DDI-PubMed.25854986.s3.e1" text="cabozantinib" /><pair ddi="false" e1="DDI-PubMed.25854986.s3.e0" e2="DDI-PubMed.25854986.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25854986.s3.e0" e2="DDI-PubMed.25854986.s3.e1" /></sentence><sentence text=" Pharmacokinetic (PK) drug-drug interactions (DDIs) were evaluated clinically between cabozantinib and (1) a CYP3A inducer (rifampin) in healthy volunteers, (2) a CYP3A inhibitor (ketoconazole) in healthy volunteers, and (3) a CYP2C8 substrate (rosiglitazone) in patients with solid tumors"><entity charOffset="86-98" id="DDI-PubMed.25854986.s4.e0" text="cabozantinib" /><entity charOffset="124-132" id="DDI-PubMed.25854986.s4.e1" text="rifampin" /><entity charOffset="180-192" id="DDI-PubMed.25854986.s4.e2" text="ketoconazole" /><entity charOffset="245-258" id="DDI-PubMed.25854986.s4.e3" text="rosiglitazone" /><pair ddi="false" e1="DDI-PubMed.25854986.s4.e0" e2="DDI-PubMed.25854986.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25854986.s4.e0" e2="DDI-PubMed.25854986.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25854986.s4.e0" e2="DDI-PubMed.25854986.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25854986.s4.e0" e2="DDI-PubMed.25854986.s4.e3" /><pair ddi="false" e1="DDI-PubMed.25854986.s4.e1" e2="DDI-PubMed.25854986.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25854986.s4.e1" e2="DDI-PubMed.25854986.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25854986.s4.e1" e2="DDI-PubMed.25854986.s4.e3" /><pair ddi="false" e1="DDI-PubMed.25854986.s4.e2" e2="DDI-PubMed.25854986.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25854986.s4.e2" e2="DDI-PubMed.25854986.s4.e3" /></sentence><sentence text=" Compared with cabozantinib given alone, coadministration with rifampin resulted in a 4"><entity charOffset="15-27" id="DDI-PubMed.25854986.s5.e0" text="cabozantinib" /><entity charOffset="63-71" id="DDI-PubMed.25854986.s5.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.25854986.s5.e0" e2="DDI-PubMed.25854986.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25854986.s5.e0" e2="DDI-PubMed.25854986.s5.e1" /></sentence><sentence text="3-fold higher plasma clearance (CL/F) of cabozantinib and a 77% decrease in cabozantinib plasma AUC0-inf , whereas coadministration with ketoconazole decreased cabozantinib CL/F by 29% and increased cabozantinib AUC0-inf by 38%"><entity charOffset="41-53" id="DDI-PubMed.25854986.s6.e0" text="cabozantinib" /><entity charOffset="76-88" id="DDI-PubMed.25854986.s6.e1" text="cabozantinib" /><entity charOffset="137-149" id="DDI-PubMed.25854986.s6.e2" text="ketoconazole" /><entity charOffset="160-175" id="DDI-PubMed.25854986.s6.e3" text="cabozantinib CL" /><entity charOffset="176-177" id="DDI-PubMed.25854986.s6.e4" text="F" /><entity charOffset="35-35" id="DDI-PubMed.25854986.s6.e5" text="F" /><pair ddi="false" e1="DDI-PubMed.25854986.s6.e5" e2="DDI-PubMed.25854986.s6.e5" /><pair ddi="false" e1="DDI-PubMed.25854986.s6.e5" e2="DDI-PubMed.25854986.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25854986.s6.e5" e2="DDI-PubMed.25854986.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25854986.s6.e5" e2="DDI-PubMed.25854986.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25854986.s6.e5" e2="DDI-PubMed.25854986.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25854986.s6.e5" e2="DDI-PubMed.25854986.s6.e4" /><pair ddi="false" e1="DDI-PubMed.25854986.s6.e0" e2="DDI-PubMed.25854986.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25854986.s6.e0" e2="DDI-PubMed.25854986.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25854986.s6.e0" e2="DDI-PubMed.25854986.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25854986.s6.e0" e2="DDI-PubMed.25854986.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25854986.s6.e0" e2="DDI-PubMed.25854986.s6.e4" /><pair ddi="false" e1="DDI-PubMed.25854986.s6.e1" e2="DDI-PubMed.25854986.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25854986.s6.e1" e2="DDI-PubMed.25854986.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25854986.s6.e1" e2="DDI-PubMed.25854986.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25854986.s6.e1" e2="DDI-PubMed.25854986.s6.e4" /><pair ddi="false" e1="DDI-PubMed.25854986.s6.e2" e2="DDI-PubMed.25854986.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25854986.s6.e2" e2="DDI-PubMed.25854986.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25854986.s6.e2" e2="DDI-PubMed.25854986.s6.e4" /><pair ddi="false" e1="DDI-PubMed.25854986.s6.e3" e2="DDI-PubMed.25854986.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25854986.s6.e3" e2="DDI-PubMed.25854986.s6.e4" /></sentence><sentence text=" Chronic coadministration with cabozantinib resulted in no significant effect on rosiglitazone plasma Cmax , AUC0-24 , or AUC0-inf "><entity charOffset="31-43" id="DDI-PubMed.25854986.s7.e0" text="cabozantinib" /><entity charOffset="81-94" id="DDI-PubMed.25854986.s7.e1" text="rosiglitazone" /><pair ddi="false" e1="DDI-PubMed.25854986.s7.e0" e2="DDI-PubMed.25854986.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25854986.s7.e0" e2="DDI-PubMed.25854986.s7.e1" /></sentence><sentence text=" In summary, chronic use of strong CYP3A inducers and inhibitors should be avoided when cabozantinib is administered, and cabozantinib at clinically relevant exposures is not anticipated to markedly affect the PK of concomitant medications via CYP enzyme inhibition"><entity charOffset="88-100" id="DDI-PubMed.25854986.s8.e0" text="cabozantinib" /><entity charOffset="122-134" id="DDI-PubMed.25854986.s8.e1" text="cabozantinib" /><pair ddi="false" e1="DDI-PubMed.25854986.s8.e0" e2="DDI-PubMed.25854986.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25854986.s8.e0" e2="DDI-PubMed.25854986.s8.e1" /></sentence><sentence text=" " /></document>